[ad_1]
On February 10, 2023 at 11:18:57 (ET) an unusually large
$304.00K block of Put contracts in Akebia Therapeutics (AKBA) was bought,
with a strike price of $2.50 / share, expiring in 35 days (on March 17, 2023).
Fintel tracks all large options trades, and the premium spent on this trade was 5.43 sigmas above the mean, placing it in the percentile of all recent large trades made in AKBA options.
Analyst Price Forecast Suggests 47.99% Upside
As of February 9, 2023,
the average one-year price target for Akebia Therapeutics is $1.66.
The forecasts range from a low of $1.26 to a high of $2.10.
The average price target represents an increase of 47.99% from its latest reported closing price of $1.12.
The projected annual revenue for Akebia Therapeutics
is $203MM, a decrease of 31.53%.
The projected annual EPS
is -$0.46.
What is the Fund Sentiment?
There are 134 funds or institutions reporting positions in Akebia Therapeutics.
This is a decrease
of
83
owner(s) or 38.25% in the last quarter.
Average portfolio weight of all funds dedicated to AKBA is 0.01%,
a decrease
of 24.14%.
Total shares owned by institutions decreased
in the last three months by 18.42% to 52,341K shares.
The put/call ratio of AKBA is 0.06, indicating a
bullish
outlook.
What are large shareholders doing?
Acadian Asset Management
holds 7,483K shares
representing 4.07% ownership of the company.
In it’s prior filing, the firm reported owning 7,339K shares, representing
an increase
of 1.92%.
The firm
decreased
its portfolio allocation in AKBA by 2.40% over the last quarter.
VEXPX – VANGUARD EXPLORER FUND Investor Shares
holds 4,698K shares
representing 2.55% ownership of the company.
No change in the last quarter.
Satter Management Co.
holds 4,653K shares
representing 2.53% ownership of the company.
No change in the last quarter.
Millennium Management
holds 3,481K shares
representing 1.89% ownership of the company.
In it’s prior filing, the firm reported owning 5,354K shares, representing
a decrease
of 53.82%.
The firm
decreased
its portfolio allocation in AKBA by 44.50% over the last quarter.
Renaissance Technologies
holds 3,016K shares
representing 1.64% ownership of the company.
In it’s prior filing, the firm reported owning 1,482K shares, representing
an increase
of 50.86%.
The firm
increased
its portfolio allocation in AKBA by 117.98% over the last quarter.
Akebia Therapeutics Background Information
(This description is provided by the company.)
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
Image and article originally from www.nasdaq.com. Read the original article here.